Kontigo Care (KONT) Q3 2024 earnings summary

Executive summary

• Achieved record-high revenue in Q3 2024 despite price competition, with positive EBIT for the third consecutive quarter.

• Monthly Recurring Revenue (MRR) at quarter-end was 2.47 MSEK, up 4.0% year-over-year, and 2.50 MSEK at report date.

• Expanded product portfolio and initiated new clinical studies and partnerships, supporting continued growth and market leadership.

Financial highlights

• Q3 2024 net sales reached 7.6 MSEK, up 6.5% year-over-year; nine-month sales totaled 22.7 MSEK, up 5.4%.

• Q3 EBIT was 0.7 MSEK (9.5% margin), down from 1.6 MSEK (22.2%) last year, impacted by one-time development and hardware transition costs.

• Q3 net income was 0.8 MSEK (0.02 SEK/share), down from 1.5 MSEK (0.06 SEK/share) year-over-year.

• Free cash flow for Q3 was -0.2 MSEK, a significant improvement from -1.4 MSEK in Q3 2023.

• Cash position at period-end was 13.4 MSEK, with a negative net debt of -9.1 MSEK.

Outlook and guidance

• No formal forecasts provided; focus remains on product development, cost control, and expansion into new markets and segments.